CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
Study Design & Technical Specifications
Sample Size / Cohort
Documented in primary study
Subject / Study Model
CNS Experimental / Clinical Model
Analytical Modalities
Primary Abstract & Repository Description
Source: medRxiv (Neurology)Editorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Translational Bottlenecks
This resource from medRxiv (Neurology) ("CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis") addresses critical scientific questions within Multiple Sclerosis (MS). Research in this domain currently faces major translational bottlenecks, including progression independent of relapse activity (PIRA), smoldering neuroinflammation, and remyelination failure across white and cortical gray matter. By focusing on key thematic elements (medRxiv Clinical, Clinical Neurology, neurology, MULTIPLE SCLEROSIS), this work contributes empirical evidence toward understanding how molecular, cellular, or systems-level alterations relate to core disease pathways such as paramagnetic rim lesions (PRLs), T2/FLAIR lesion volume, oligoclonal bands, EBV titers, and EDSS progression metrics. Integrating these findings into the broader open science ecosystem helps reduce fragmentation across independent laboratories and accelerates hypothesis verification.
日本語解説を表示 (Japanese)
medRxiv (Neurology)より公開された本リソース（「CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis」）は、多発性硬化症（MS）領域における重要な学術的・臨床的課題に焦点を当てています。現在の多発性硬化症（MS）研究では、再発に依存しない進行（PIRA）、くすぶり型（smoldering）神経炎症・ミクログリア活性化の持続、および脱髄病変における再髄鞘化不全の克服といったトランスレーショナルリサーチ上のボトルネックが存在します。本リソースは関連キーワード（medRxiv Clinical, Clinical Neurology, neurology, MULTIPLE SCLEROSIS）を軸として、常磁性リム病変（PRL）、T2/FLAIR病変体積、オリゴクローナルバンド、血清NfL/GFAP、およびEDSS進行指標などの主要経路や病態メカニズムの理解に資する知見・データを提供しており、研究室や機関ごとに分散しがちな知見をオープンサイエンス基盤上で統合・検証する上で重要な位置づけを持ちます。
2. Methodology & Data Architecture Value
Methodologically, this preprint integrates Clinical Neurology, Preprint Article within a CNS Experimental / Clinical Model framework (cohort/experimental samples documented in source protocol). Curated via medRxiv (Neurology) (DOI: 10.64898/2026.09.23.26363841), the analytical approach provides structured insights into Multiple Sclerosis (MS) pathophysiology. Evaluating the reported outcomes alongside Clinical Neurology, Preprint Article technical specifications allows researchers to benchmark effect sizes, assay sensitivity, and experimental reproducibility against established reference cohorts.
日本語解説を表示 (Japanese)
方法論の観点から、本研究（種別: preprint）は神経科学実験・臨床モデル（規模: 原著プロトコルに記載されたコホート・実験サンプル）を対象に「Clinical Neurology, Preprint Article」を適用しています。medRxiv (Neurology)に収録された本知見（DOI: 10.64898/2026.09.23.26363841）は、多発性硬化症（MS）の病態生理や評価指標を精緻に分析する枠組みを提示しています。採用されたモダリティ（Clinical Neurology, Preprint Article）の測定仕様と報告された効果量を既存の参照コホートと比較することで、測定感度のベンチマークや実験プロトコルの再現性評価に直接活用できます。
3. Secondary Analysis & Reusability Scenarios
Researchers and computational neuroscientists can reuse this resource across multiple secondary workflows: (1) Cross-Cohort Harmonization & Meta-Analysis — combining these Clinical Neurology, Preprint Article records with complementary repositories (such as OpenNeuro, DANDI, Agora, or Europe PMC) to increase statistical power; (2) Computational Benchmarking & Machine Learning — utilizing the documented features (medRxiv Clinical, Clinical Neurology, neurology, MULTIPLE SCLEROSIS) as training, validation, or out-of-distribution test sets for predictive biomarker discovery in Multiple Sclerosis (MS); and (3) Experimental Protocol Alignment — referencing the study design (CNS Experimental / Clinical Model, cohort/experimental samples documented in source protocol) to calibrate sample size calculations (power analysis) and endpoint selection for upcoming preclinical or clinical studies.
日本語解説を表示 (Japanese)
本リソースは以下のような二次解析・再利用シナリオに幅広く活用可能です。(1) コホート横断的ハーモナイゼーションとメタ解析：本リソースの「Clinical Neurology, Preprint Article」データを他の公開リポジトリ（OpenNeuro、DANDI、Agora、ADNI等）の同種データと統合し、統計的検出力（Statistical Power）を高めた統合解析を実施する。(2) 機械学習・バイオマーカー予測モデルの検証：抽出された特徴量や関連因子（medRxiv Clinical, Clinical Neurology, neurology, MULTIPLE SCLEROSIS）を、多発性硬化症（MS）の進行予測・サブタイプ分類モデルの外部検証（External Validation）や転移学習データとして利用する。(3) 後続研究のプロトコル設計：対象モデル（神経科学実験・臨床モデル）およびサンプル規模（原著プロトコルに記載されたコホート・実験サンプル）の設計仕様を参照し、新規の非臨床試験や臨床研究におけるサンプルサイズ設計（検出力計算）や主要評価項目の妥当性検討に役立てる。
4. Methodological Limitations & Caveats
Because this record is indexed as a preprint, its experimental conclusions have not yet completed formal journal peer review; downstream clinical or therapeutic decisions should await peer-reviewed validation. Specifically, when interpreting Clinical Neurology, Preprint Article results in Multiple Sclerosis (MS), researchers must control for confounding variables (such as age, sex, post-mortem interval, scanner/instrument drift, or medication state) and verify compliance with open-access attribution requirements (cc_no).
日本語解説を表示 (Japanese)
本レコードはプレプリント（査読前論文）として公開されているため、実験結果や結論は学術誌による正式なピアレビュー完了前の段階にあります。臨床応用や確定的な解釈にあたっては、後続の査読付き出版版の検証結果を併せて確認する必要があります。特に多発性硬化症（MS）における「Clinical Neurology, Preprint Article」データの解釈では、年齢・性別・罹病期間・測定機器のキャリブレーション差・併用薬などの交絡因子を適切に補正することが推奨されます。また、データや図表の二次利用時は提供元（medRxiv (Neurology)）の利用条件（cc_no）および適切な引用表記を遵守してください。
Data Access, Reproducibility & Analysis Starter Guide
FAIR Open Science & Clinical Metadata Verification Protocol
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This resource is indexed under FAIR (Findable, Accessible, Interoperable, and Reusable) open-science metadata standards, enabling programmatic cross-referencing across Europe PMC, Semantic Scholar, ClinicalTrials.gov, and CNS Open Data.
Programmatic Data Retrieval (Python Starter Code & Recommended SDKs)
Python Quickstart: Query Europe PMC & Semantic Scholar Metadata
# Fetch structured bibliographic & open-access data via Europe PMC REST API
import urllib.request
import urllib.parse
import json
query = "DOI:\"10.64898/2026.09.23.26363841\""
url = f"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query={urllib.parse.quote(query)}&format=json&resultType=core"
with urllib.request.urlopen(url, timeout=10) as response:
payload = json.loads(response.read().decode("utf-8"))
results = payload.get("resultList", {}).get("result", [])
if results:
record = results[0]
print("Title:", record.get("title"))
print("Journal / Source:", record.get("journalTitle") or record.get("bookOrReportDetails"))
print("Cited By Count:", record.get("citedByCount", 0))Standardized 4-Step Workflow & Governance Checklist
Standardized Acquisition & Preprocessing Workflow
1. Programmatic Metadata & Full-Text OA Retrieval
Query Europe PMC or Crossref REST APIs using the persistent DOI/URL to retrieve structured XML full text, supplementary tables, and grant links.
2. Study Design & Cohort Eligibility Screening
Extract sample size, inclusion/exclusion criteria, and primary outcome endpoints for systematic review (PRISMA) inclusion.
3. Data Availability & Supplementary Repository Linkage
Locate accession numbers (GEO, SRA, OpenNeuro, DANDI, Zenodo, Figshare) referenced in the Data Availability section.
4. Citation Graph & Replication Tracking
Monitor supporting and contrasting citations over time to verify whether key findings have been independently replicated.
Reproducibility & Governance Checklist
- Verify whether the source is a peer-reviewed journal publication or an unrefereed preprint before clinical citation.
- Check supplementary data licenses (CC-BY / CC0) when extracting figures or summary statistics for meta-analyses.
- Cross-reference NCT clinical trial identifiers when evaluating therapeutic efficacy or biomarker endpoints.
Tags & Modalities
Bibliometrics, Peer-Review Status & Citation Export
Cross-referenced via Semantic Scholar, Europe PMC & bioRxiv
1. Citation Metrics & Context Breakdown
Citation Context Breakdown
2. Peer-Review Validation & Revision History
Preprint Article (bioRxiv / medRxiv — Awaiting Peer Review)
This article is indexed as an unrefereed preprint. Our ingestion pipeline periodically queries Europe PMC and bioRxiv/medRxiv APIs to automatically link the final peer-reviewed journal DOI once published.
3. Standardized Academic Citation & BibTeX Export
Klistorner, S. et al. (2026). CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis. medRxiv (Neurology). https://doi.org/10.64898/2026.09.23.26363841
@article{s.2026medr,
title = {CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis},
author = {Klistorner, S. and Hotchkin, M. and Greenberg, B. and Rynders, A. and Glanzman, R.},
year = {2026},
journal = {medRxiv (Neurology)},
howpublished = {\url{https://doi.org/10.64898/2026.09.23.26363841}},
doi = {10.64898/2026.09.23.26363841},
note = {CNS Open Data: multiple_sclerosis}
}Related Multiple Sclerosis Research & Datasets
Explore All DatasetsMSDA: COVID19 GDSI LocalDashboard - Federated MS Data Toolkit
Official open-source repository and tool for Multiple Sclerosis federated research and data harmonization under MS-DATA-ALLIANCE.
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data.
Dietary Patterns and Nutritional Factors in Multiple Sclerosis: A Narrative Review
Research article from Europe PMC.
MSDA Core Dataset (CDS): Standardized Global Real-World Data Harmonization Framework for Multiple Sclerosis
The MSDA Core Dataset (CDS) establishes a 44-variable international harmonization schema mapped to the OMOP Common Data Model, enabling privacy-preserving federated analytics across global Multiple Sclerosis registries.
MSDA Global Registry & Cohort Metadata Discovery Catalogue (BigMS Network)
A centralized metadata discovery catalogue indexing over 30 national and international MS registries (>120,000 patients), detailing variable availability for EDSS, relapse history, MRI, fluid biomarkers, and DUA governance.
Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».
Multiple sclerosis (MS) is a complex, multifactorial neurodegenerative disease with an aetiology that is still partially elusive. Several risk factors are associated with MS development including genetic predisposition and various environmental stressors; however, recently, viral infections have gained significant attention as a crucial environmental trigger. Despite the well-established link between Epstein-Barr virus (EBV) and MS susceptibility, a single-pathogen model fails to clearly characterise the molecular cascades driving the disease, suggesting that the transition from infection to autoimmune response involves more than one viral agent. In this review we examine the speculation that the interactions among different neurotropic viruses could serve a collective causative role in MS, which is under-researched in the literature at present. We summarise contradictory evidence on the role of different viral agents, including the Herpesviridae family (Human Cytomegalovirus, EBV, Herpes Simplex Viruses HSV-1 and HSV-2, and Varicella Zoster Virus), Paramyxoviridae family (Measles Virus and Rubella Virus), Influenza virus, SARS-CoV-2, and Human Endogenous Retroviruses (HERVs). Through interplay within shared molecular pathways, immune modulation, and activation of latent infections, these viruses may collectively influence the inflammatory and demyelinating processes that characterise MS. This review evaluates the etiological role of viral interplay in MS through the cumulative and interactive effects of these pathogens. The available epidemiological, immunological, and experimental data converge on the concept that viral co-exposures act synergistically to shape MS susceptibility in genetically predisposed individuals. Characterising these viral interactions presents a new research direction for the identification of novel biomarkers and the development of preventative strategies through the targeted control of viral networks.
Active Clinical Trials & Pipeline in Multiple Sclerosis
View Clinical PipelineMSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
MSDA: GDSI Mock DataGenerator - GDSI Mock data generator
Related Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.